Procyon Corporation (PCYN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Procyon Corporation (PCYN) trades at $0.20 with AI Score 54/100 (Grade B). Procyon Corporation develops and markets medical products for treating skin conditions like pressure ulcers and dermatitis. Market cap: $1.63M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for PCYN: PCYN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PCYN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PCYN: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Procyon Corporation (PCYN) Healthcare & Pipeline Overview
Procyon Corporation focuses on developing and marketing specialized medical products for skin and wound care, addressing conditions like pressure ulcers and dermatitis. With a diverse product line including AMERIGEL and HELIX3 brands, the company distributes through multiple channels, targeting both institutional and retail customers in the United States.
What Is the Investment Thesis for PCYN?
Procyon Corporation operates in the niche market of advanced wound care and skin treatment products. With a market capitalization of $1.63M and a P/E ratio of 45.16, the company's financial performance reflects both its growth potential and the challenges of operating in a competitive industry. A gross margin of 31.9% indicates moderate profitability in its product sales. The company's growth is tied to expanding its distribution network and introducing innovative products within its existing portfolio. Key risks include competition from larger players and the need for continuous product development to maintain market relevance. The company's beta of -1.03 suggests a low correlation with the overall market, potentially offering some stability in volatile conditions. Success hinges on effective marketing and sales strategies to penetrate a fragmented market.
Based on FMP financials and quantitative analysis
PCYN Key Highlights
- Market capitalization of $1.63M indicates the company's current valuation in the market.
- P/E ratio of 45.16 reflects investor expectations for future earnings growth.
- Gross margin of 31.9% demonstrates the profitability of Procyon's product sales.
- Profit margin of 0.5% shows the net profitability after all expenses.
- Beta of -1.03 suggests the stock has a low correlation with the overall market.
Who Are PCYN's Competitors?
PCYN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PCYN's Key Strengths?
- Specialized product portfolio in wound and skin care.
- Established brand names (AMERIGEL, HELIX3).
- Multi-channel distribution network.
- Proprietary medical products.
What Are PCYN's Weaknesses?
- Small market capitalization.
- Low profit margin.
- Limited geographic reach.
- Dependence on distributors.
What Could Drive PCYN Stock Higher?
- Potential FDA approval for new wound care products.
- Expansion of direct-to-consumer sales channels.
- Strategic partnerships with healthcare providers.
- Development and launch of innovative wound care solutions.
What Are the Key Risks for PCYN?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements and compliance costs.
- Economic downturn affecting healthcare spending.
- Dependence on distributors for product sales.
- Low trading volume and liquidity in OTC market.
What Are the Growth Opportunities for PCYN?
- Expanding Product Line: Procyon can focus on developing and launching new, innovative wound care products that cater to specific patient needs. The global wound care market is projected to reach $22 billion by 2027, presenting a significant opportunity for Procyon to capture a larger market share through product innovation and differentiation. Timeline: Ongoing.
- Geographic Expansion: Procyon currently focuses primarily on the United States. Expanding into international markets, particularly in Europe and Asia, could significantly increase its revenue base. These regions have a growing demand for advanced wound care products due to aging populations and increasing healthcare expenditures. Timeline: 2-3 years.
- Strategic Partnerships: Forming strategic alliances with hospitals, clinics, and other healthcare providers can enhance Procyon's distribution network and market reach. Collaborations can also facilitate the development of co-branded products and services, creating additional revenue streams. Timeline: Ongoing.
- Direct-to-Consumer Sales: Enhancing its online presence and direct-to-consumer sales channels can allow Procyon to reach a broader customer base and increase brand awareness. This approach can also improve profit margins by reducing reliance on distributors. Timeline: 1 year.
- Acquisitions: Acquiring smaller companies with complementary product lines or technologies can provide Procyon with access to new markets and expertise. This strategy can accelerate growth and diversify the company's product portfolio. Timeline: Opportunistic.
What Opportunities Does PCYN Have?
- Expanding product line with innovative solutions.
- Geographic expansion into international markets.
- Strategic partnerships with healthcare providers.
- Direct-to-consumer sales growth.
What Threats Does PCYN Face?
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements.
- Need for continuous product development.
- Economic downturn affecting healthcare spending.
What Are PCYN's Competitive Advantages?
- Proprietary medical products for niche markets.
- Established brand names like AMERIGEL and HELIX3.
- Multi-channel distribution network.
- Specialized product offerings in wound and skin care.
What Does PCYN Do?
Procyon Corporation, established in 1987 and based in Clearwater, Florida, develops and markets proprietary medical products designed for the treatment of various skin conditions, including pressure ulcers, stasis ulcers, wounds, dermatitis, and inflammation. The company's product portfolio encompasses advanced skin and wound care solutions, featuring hydrogel wound dressings, post-op surgical kits, saline wound washes, care lotions, and barrier lotions, all marketed under the AMERIGEL brand. Additionally, Procyon offers Bioactive Collagen products in powder and matrix forms under the HELIX3 brand, catering to advanced wound care needs. Procyon's product range extends to include traditional wound care products such as calcium alginate, foam, gauze, and hydrocolloid dressings. These products are available individually and within wound care kits under the AMERX brand, which also includes collagen matrix and powder options. The company also offers compression garments under the EXTREMIT-EASE name. Procyon distributes its products through a multi-channel approach, targeting institutional customers like hospitals, wound care clinics, nursing homes, home health agencies, physicians, and healthcare practitioners. The company also reaches retail customers through direct sales, internet sales, and partnerships with independent and retail chain drug stores. Procyon's focus on specialized wound and skin care products allows it to address specific needs within the broader healthcare market.
What Products and Services Does PCYN Offer?
- Develops medical products for treating pressure ulcers.
- Markets products for stasis ulcers and wounds.
- Offers solutions for dermatitis and inflammation.
- Provides hydrogel wound dressing products.
- Sells post-op surgical kits and saline wound washes.
- Markets care lotions and barrier lotions under the AMERIGEL brand.
- Offers Bioactive Collagen products under the HELIX3 brand.
How Does PCYN Make Money?
- Develops and manufactures proprietary medical products.
- Sells products through distributors to institutional customers.
- Utilizes direct sales and internet sales channels.
- Partners with independent and retail chain drug stores.
What Industry Does PCYN Operate In?
Procyon Corporation operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, stringent regulatory requirements, and a constant need for innovation. The market for wound care and skin treatment products is driven by an aging population, increasing prevalence of chronic diseases like diabetes, and growing awareness of advanced wound care technologies. Procyon competes with both large pharmaceutical companies and smaller specialized firms, requiring a focus on niche markets and differentiated products to maintain a competitive edge.
Who Are PCYN's Key Customers?
- Hospitals
- Wound care clinics
- Nursing homes
- Home health agencies
- Physicians and healthcare practitioners
- Retail customers
Company Profile
Procyon Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Clearwater, US. The company is led by CEO Justice W. Anderson. PCYN has traded publicly since 1996.
F-Score 2/9Financial Health
Procyon Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.03 places it in the grey zone, a middle ground that warrants monitoring.
ROE 1%Key Financial Metrics
Return on equity for Procyon Corporation stands at 1.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.0%, showing how much profit it generates from its asset base. PCYN trades at a trailing price-to-earnings ratio of 48.28, above the Healthcare sector average of ~23x. Its free cash flow yield is -30.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.
PCYN Valuation & Market Position
With a $1.63M market cap, Procyon Corporation sits in the micro-cap segment of the market. Relative to its peer group, PCYN's quantitative score of 54/100 is below the peer average of 66/100.
PCYN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Procyon Corporation's future, indicating that leadership believes in the company's potential.
- Community sentiment has turned positive, with discussions highlighting recent product developments that could boost revenue.
- Analysts are noting the company's strategic partnerships, which may enhance market reach and operational efficiency.
- The overall market perception has shifted favorably, with increased interest in companies focused on innovative solutions in their sector.
Bear Case
- Concerns about competition in Procyon's sector have surfaced, with some community members voicing skepticism about their market position.
- Recent earnings reports have raised questions about sustainability, leading to bearish sentiment among some investors.
- There have been discussions about potential regulatory challenges that could impact Procyon's operations negatively.
- Overall market volatility has created a cautious atmosphere, with some investors wary of new entries in the current climate.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PCYN Latest News
No recent news available for PCYN.
PCYN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PCYN.
Price Targets
Wall Street price target analysis for PCYN.
PCYN MoonshotScore
What does this score mean?
The MoonshotScore rates PCYN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Justice W. Anderson
CEO
Justice W. Anderson serves as the CEO of Procyon Corporation, managing a team of 19 employees. His background includes experience in the healthcare industry, with a focus on developing and marketing specialized medical products. Anderson's leadership is crucial in guiding Procyon's strategic direction and ensuring the company's growth in the competitive wound care market. His expertise in product development and distribution strategies is vital for Procyon's success.
Track Record: Under Justice W. Anderson's leadership, Procyon Corporation has focused on expanding its product line and strengthening its distribution network. Key milestones include the introduction of new wound care products and the enhancement of direct-to-consumer sales channels. His strategic decisions have aimed at improving the company's market position and profitability.
PCYN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Procyon Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading can be highly speculative. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and market position.
- Research the background and experience of the management team.
- Evaluate the company's stock price and trading volume.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Longevity of the company's operations (incorporated in 1987).
- Presence of established brand names (AMERIGEL, HELIX3).
- Multi-channel distribution network.
- Focus on specialized medical products.
PCYN Healthcare Stock FAQ
What does Procyon Corporation do?
Procyon Corporation develops, manufactures, and markets specialized medical products for wound and skin care. Its product portfolio includes advanced wound dressings, post-op surgical kits, and collagen-based products under the AMERIGEL and HELIX3 brands. The company distributes its products through a multi-channel approach, targeting institutional customers like hospitals and clinics, as well as retail customers through direct sales and partnerships with drug stores. Procyon focuses on providing solutions for conditions such as pressure ulcers, stasis ulcers, and dermatitis.
What do analysts say about PCYN stock?
As of 2026-03-16, formal analyst ratings for Procyon Corporation (PCYN) are not widely available, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence, considering factors such as the company's financial performance, product pipeline, and competitive landscape. Key valuation metrics include the P/E ratio of 45.16 and a gross margin of 31.9%. Growth considerations involve the company's ability to expand its market reach and introduce new products.
What are the main risks for PCYN?
Procyon Corporation faces several risks, including intense competition from larger pharmaceutical companies, stringent regulatory requirements, and potential economic downturns affecting healthcare spending. As an OTC-listed company, PCYN is subject to lower levels of regulatory oversight and may experience limited trading volume and liquidity. Dependence on distributors and the need for continuous product development also pose ongoing challenges. Investors should carefully assess these risks before investing in PCYN.
What are the key factors to evaluate for PCYN?
Procyon Corporation (PCYN) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does PCYN data refresh on this page?
PCYN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PCYN's recent stock price performance?
Procyon Corporation (PCYN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in wound and skin care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PCYN overvalued or undervalued right now?
Valuing Procyon Corporation (PCYN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PCYN?
Before investing in Procyon Corporation (PCYN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market investments carry significant risks.